U.S. Markets closed
S&P 500
3,351.28+2.12(+0.06%)Nasdaq
11,010.98-97.09(-0.87%)Russell 2000
1,569.18+24.56(+1.59%)
Protagonist Therapeutics, Inc. (PTGX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.96+1.51 (+9.18%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 16.45 |
| Open | 16.50 |
| Bid | 17.96 x 800 |
| Ask | 17.90 x 1400 |
| Day's Range | 16.50 - 18.26 |
| 52 Week Range | 4.47 - 19.67 |
| Volume | 356,776 |
| Avg. Volume | 1,120,353 |
| Market Cap | 640.588M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.55 |
| Earnings Date | Nov 04, 2020 - Nov 09, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.00 |
- Zacks
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.51% and 63.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Protagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported financial results for the second quarter ended June 30, 2020, and provided an update on clinical development programs.
- Zacks
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
© 2020 Verizon Media. All rights reserved.
